Sujana Movva, MD

Request an Appointment Online - Click Here New patients can request an appointment online or call

Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111-2497

Sujana Movva, MD

Sujana Movva, MD

Patient Stories from Fox Chase Patients Dr. Movva's
Patient Stories

Sujana Movva, MD


Assistant Professor

Meet other members of the
sarcoma treatment team,

melanoma treatment team,
or the
neuro-oncology team


Clinical Expertise:

Sarcoma, melanoma, neuro-oncology


American Board of Internal Medicine;
American Board of Medical Oncology

Medical Education

MD, University of Western Ontario, London, Canada, 2003


Residency in Internal Medicine, Michigan State University, Mclaren Regional Medical Center, Flint, MI, 2004-2007


Fellowship in Hematology Oncology, University of New Mexico, Albuquerque, NM, 2007-2010 

Professional Societies

American Society of Clinical Oncology;
Connective Tissue Oncology Society  

Research Interests

Drug development, Biomarkers, Sarcoma


Dr. Movva on My NCBI

  1.  Norberg SM, Movva S. Role of genetic and molecular profiling in sarcomas. Curr Treat Options Oncol. 2015 May;16(5):339. doi: 10.1007/s11864-015-0339-3. PubMed PMID: 25939540.
  2. Movva S, Wen W, Chen W, Millis SZ, Gatalica Z, Reddy S, von Mehren M, Van Tine BA. Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets. Oncotarget. 2015 Mar 26. [Epub ahead of print] PubMed PMID: 25906748.
  3. Verschraegen CF, Movva S, Ji Y, Schmit B, Quinn RH, Liem B, Bocklage T, Shaheen M. A phase I study of the combination of temsirolimus with irinotecan for metastatic sarcoma. Cancers (Basel). 2013 Apr 11;5(2):418-29. doi: 10.3390/cancers5020418. PubMed PMID: 24216984; PubMed Central PMCID: PMC3730334.
  4. Cardona K, Movva S. Issues in the management of high-risk localized sarcomas. Curr Probl Cancer. 2013 Mar-Apr;37(2):62-73. doi: 10.1016/j.currproblcancer.2013.03.002. PubMed PMID: 23719331.
  5. Cardona K, Williams R, Movva S. Multimodality therapy for advanced or metastatic sarcoma. Curr Probl Cancer. 2013 Mar-Apr;37(2):74-86. doi: 10.1016/j.currproblcancer.2013.03.003. Review. PubMed PMID: 23719332.
  6. Movva S. Emerging therapies for sarcoma. Curr Probl Cancer. 2013 Mar-Apr;37(2):87-101. doi: 10.1016/j.currproblcancer.2013.03.004. Review. PubMed PMID: 23719333.
  7. Verschraegen CF, Arias-Pulido H, Lee SJ, Movva S, Cerilli LA, Eberhardt S, Schmit B, Quinn R, Muller CY, Rabinowitz I, Purdy M, Snyder D, Bocklage T. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann Oncol. 2012 Mar;23(3):785-90. doi: 10.1093/annonc/mdr299. Epub 2011 Jul 11. PubMed PMID: 21746804.
  8. Movva S, Verschraegen C. Systemic management strategies for metastatic soft tissue sarcoma. Drugs. 2011 Nov 12;71(16):2115-29. doi: 10.2165/11594500-000000000-00000. Review. PubMed PMID: 22035513.
  9. Movva S, Verschraegen CF, Rabinowitz I, Mangalik A, Parks V, Lee FC. Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors. Melanoma Res. 2011 Feb;21(1):76-9. doi: 10.1097/CMR.0b013e32833d3293. PubMed PMID: 21169871.
  10. Movva S, Verschraegen C. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management. Expert Opin Biol Ther. 2009 Feb;9(2):231-41. doi: 10.1517/14712590802643347 . Review. PubMed PMID: 19236253.